Moderate Aortic Stenosis: We Should Start Assessing It More Thoroughly

Moderate aortic stenosis (MAS) encompasses a broader spectrum than severe aortic stenosis. However, its progression has not yet been fully elucidated. While there are reports suggesting that this condition is not as benign as initially believed, there is a need to consider early interventions in certain instances.

Estenosis aórtica moderada: debemos comenzar a evaluarla mejor

Researchers conducted an analysis from January 2016 to June 2020 involving 674 patients with MAS. This category was defined as an aortic valve area between 1 cm² and 1.5 cm², a mean gradient between 20 mmHg and 40 mmHg, and a peak velocity of less than 4 m/s.

Patient average age was 75 years and 57% of subjects were male. Among the total, 81% had hypertension, 38% had diabetes, 49% had coronary artery disease, 28% had had a stroke, 44% had atrial fibrillation, 75% had elevated NT-pro BNP levels, and 70% had an eGFR <60. Ejection fraction was 60%; the mean gradient, 33 mmHg; peak velocity, 3.42 m/s; and aortic valve area, 1.2 cm². There was severe calcification in 13% of cases and moderate calcification in 72% of them, and 10% had bicuspid valve.

During one year of follow-up, there were major adverse cardiovascular events (MACE) in 45.3% of cases, while mortality reached 19.6%. A total of 114 patients (16.9%) required aortic valve replacement, of which 45 underwent transcatheter aortic valve implantation (TAVI) and 21.4% were hospitalized due to heart failure.

Read also: bRight: Impact and Safety of the TriClip Device in a Real-World Cohort.

Predictors of MACE included elevated levels of NT-pro BNP, presence of diabetes, elevated mitral E-wave, and the existence of atrial fibrillation at the time of diagnosis.

Conclusion

These findings shed light on the relatively unfavorable short-term prognosis and patient stratification in moderate aortic stenosis. Furthermore, they support the need for randomized studies to evaluate the effectiveness of percutaneous treatments, such as aortic valve replacement, in this specific population.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Predictors of Major Adverse Cardiovascular Events in Patients With Moderate Aortic Stenosis: Implications for Aortic Valve Replacement.

Reference: Travis Howard, et al. Circ Cardiovasc Imaging. 2023;16:e015475. DOI: 10.1161/CIRCIMAGING.123.015475.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...